99 related articles for article (PubMed ID: 17050077)
21. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
Mhawech-Fauceglia P; Saxena R; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
J Clin Pathol; 2007 Jun; 60(6):709-14. PubMed ID: 16837628
[TBL] [Abstract][Full Text] [Related]
22. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
23. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
24. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.
Howitt BE; Emori MM; Drapkin R; Gaspar C; Barletta JA; Nucci MR; McCluggage WG; Oliva E; Hirsch MS
Am J Surg Pathol; 2015 Oct; 39(10):1411-9. PubMed ID: 26135559
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T
Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
[TBL] [Abstract][Full Text] [Related]
27. Secretagogin is a novel marker for neuroendocrine differentiation.
Birkenkamp-Demtröder K; Wagner L; Brandt Sørensen F; Bording Astrup L; Gartner W; Scherübl H; Heine B; Christiansen P; Ørntoft TF
Neuroendocrinology; 2005; 82(2):121-38. PubMed ID: 16449819
[TBL] [Abstract][Full Text] [Related]
28. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Cohen AJ; Bunn PA; Franklin W; Magill-Solc C; Hartmann C; Helfrich B; Gilman L; Folkvord J; Helm K; Miller YE
Cancer Res; 1996 Feb; 56(4):831-9. PubMed ID: 8631021
[TBL] [Abstract][Full Text] [Related]
29. Miscellaneous primary tumors and metastatic tumors of the uterine cervix.
Clement PB
Semin Diagn Pathol; 1990 Aug; 7(3):228-48. PubMed ID: 2171127
[TBL] [Abstract][Full Text] [Related]
30. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis.
Wang DG; Johnston CF; Buchanan KD
Cancer; 1997 Aug; 80(4):668-75. PubMed ID: 9264349
[TBL] [Abstract][Full Text] [Related]
31. PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies.
Morgenstern DA; Hasan F; Gibson S; Winyard P; Sebire NJ; Anderson J
Am J Clin Pathol; 2010 Mar; 133(3):407-15. PubMed ID: 20154279
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
[TBL] [Abstract][Full Text] [Related]
33. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.
Zhai QJ; Ozcan A; Hamilton C; Shen SS; Coffey D; Krishnan B; Truong LD
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):323-32. PubMed ID: 20216401
[TBL] [Abstract][Full Text] [Related]
34. Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas.
Jakobsen AM; Ahlman H; Wängberg B; Kölby L; Bengtsson M; Nilsson O
J Pathol; 2002 Jan; 196(1):44-50. PubMed ID: 11748641
[TBL] [Abstract][Full Text] [Related]
35. Biology and novel therapeutics for neuroendocrine tumors of the lung.
Jafri N; Salgia R
J Biol Regul Homeost Agents; 2004; 18(3-4):275-90. PubMed ID: 15786694
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
37. Small cell neuroendocrine carcinoma: cytologic findings in a breast aspirate.
Ali SZ; Miller BT
Acta Cytol; 1997; 41(4):1237-40. PubMed ID: 9250328
[No Abstract] [Full Text] [Related]
38. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies.
Spieler P; Gloor F
Acta Cytol; 1985; 29(5):753-67. PubMed ID: 2996273
[TBL] [Abstract][Full Text] [Related]
39. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
Travis WD
Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
[TBL] [Abstract][Full Text] [Related]
40. Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha).
Dirnhofer S; Freund M; Rogatsch H; Krabichler S; Berger P
Hum Pathol; 2000 Aug; 31(8):966-72. PubMed ID: 10987258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
